MESO Q2 2025 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-6.8% YoY

Gross Profit

-$2M-107.8% margin

Operating Income

-$21M-1306.7% margin

Net Income

-$24M-1518.8% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$653M

Total Liabilities

$192M

Stockholders' Equity

$461M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	-6.8%
Gross Profit	-$2M	-$8M	+78.7%
Operating Income	-$21M	-$20M	-2.8%
Net Income	-$24M	-$16M	-47.3%